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Introduction
Patients affected by thalassaemia major receive 
transfusion of red blood cells from the time of diagnosis, 
which is usually made in the first 2-3 years of life. As 
a consequence, they are exposed lifelong to the risk of 
acquiring blood-borne viral infections. The risk of the 
major blood transmissible viral infections, including 
hepatitis B and C viruses and human immunodeficiency 
virus, continues to decline because of specific analyses 
carried out in samples from blood donors. However, new 
viruses are becoming a concern. Recently, there have 
been small epidemics of West Nile and Chikungunya 
virus infections so that donor testing by nuclear antigens 
has been implemented in several countries1. 
Simian Virus 40 (SV40) is a viral agent of the Asian 
macaque (Macacus rhesus), which is its natural host. 
Accumulating data suggest that SV40 is also a human 
virus, able to spread by different routes. The presence 
of SV40 sequences and the expression of its viral 
antigens have been found in human neoplasms and 
normal tissues, including blood specimens, of children 
and adults, whereas specific antibodies against this virus 
were detected in serum samples of normal subjects and 
patients affected by tumours2-8. However, contrasting 
reports have appeared in the literature on the presence of 
SV40 in humans and its association with neoplasms3,5,9,10. 
As a consequence of these results, considerable debate 
has developed in the scientific community2,3,5,11,12. 
Although SV40 sequences and serum antibodies against 
this viral agent were detected in blood samples, no 
extensive data exist on the transmission of SV40 through 
blood transfusion4,5,13. We hypothesised that SV40 might 
be transmitted with blood transfusion. In order to test 
this hypothesis, we investigated the presence of anti-
SV40 antibodies in multiply transfused patients with 
thalassaemia major. 
Background. Simian virus 40 (SV40) is a small DNA tumour virus. Footprints of the virus have 
been detected in different humam lymphoproliferative disorders and in blood specimens of blood from 
healthy blood donors. This study was carried out to verify whether SV40 antibodies can be detected 
in serum samples from multiply transfused patients with thalassaemia major. 
Materials and methods. An indirect enzyme-linked immunosorbent assay was employed, using 
SV40 specific synthetic peptides mimicking the antigens of the viral capsid proteins 1-2-3, to test 
for the presence of antibodies to SV40 in serum samples taken from patients affected by transfusion-
dependent thalassaemia major (n=190) and healthy blood donors (n=251). 
Results. The prevalence of antibodies against SV40 was higher in patients than in controls (24% 
vs 17%). The prevalence increased and was significantly higher in the older age group of patients 
affected by thalassemia major than in controls (38% vs 20%, p<0.04). 
Discussion. The higher prevalence of serum antibodies against simian virus 40 in older, multiply 
transfused patients with thalassamia major than in controls suggests that this virus, or a closely related 
yet unknown human polyomavirus, could have been transmitted in the past by transfusion with 
whole blood. At the same time, our data indicate no significant differences in prevalence of SV40 
antibodies in patients and controls of younger age thus suggesting that current transfusion methods 
with leucodepletion and filtered red cells are safe.
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Materials and methods
Patients
Serum samples were collected from thalassaemia 
patients. Written informed consent was obtained from 
patients treated between 2007 and 2013 at: (i) the 
Department of Paediatrics, University of Ferrara, (ii) 
Department of Internal Medicine, University of Milan 
and (iii) Department of Haematology, Sant'Eugenio 
Hospital, Rome. Italy. Control serum samples were 
obtained from blood donors4-7. Serum samples 
were analysed at the Sections of Microbiology, and 
Experimental Biology Cell and Molecular Genetics, 
University of Ferrara, for the presence of anti-SV40 
antibodies by an indirect enzyme-linked immunosorbent 
assay (ELISA) employing SV40-specific synthetic 
peptides mimicking the VP1-3 antigens. 
Since viruses are transmitted more easily with 
transfusions containing leucocytes, patients and controls 
were subdivided in three cohorts according to age: 20-30 
years, 31-40 years and 41-50 years. The oldest cohort 
included patients born before 1965, when treatment with 
blood components was introduced and these patients 
had, therefore, received whole blood. The cohort aged 
31-40 years included patients born between 1965 and 
1985, who up to 1985, had received concentrated red 
blood cells. The youngest cohort, comprising patients 
born after 1985, the year when leucodepletion was 
introduced in our blood banks, had received only 
concentrated and filtered red blood cells. The study was 
approved by the County Ethical Committee of Ferrara.
Synthetic peptides
Computer-assisted analyses allowed us to select 
two specific SV40 peptides, from the late viral region 
by comparing the three capsid proteins, VP 1-2-3 from 
SV40, with the amino acids of the human BK (BKV) and 
JC (JCV) polyomaviruses which are highly homologous 
with SV40, as well as with other, less homologous 
polyomaviruses4,5. Previous ELISA results indicated 
that the two SV40 peptides did not cross-react with the 
BKV and JCV hyperimmune sera that were employed as 
controls4,5. The two peptides belong to the VP1/VP2/VP3 
viral capsid proteins (web site, http://www.ncbi.nlm.
nih.gov/nuccore). The amino acid sequences of the two 
peptides, known as VP1 B and VP2/3 C, are as follows:
VP1 B: NH2- NPDEHQKGLSKSLAAEKQFTDDSP- COOH
VP2/3 C: NH2- IQNDIPRLTSQELERRTQRYLRD- COOH.
VP1 B and VP2/3 C mimotopes were selected as they 
react specifically in indirect ELISA with the rabbit 
hyperimmune serum that had been experimentally 
immunised with SV40 (positive control serum). BKV 
and JCV hyperimmune sera did not react with VP1 B or 
VP2/3 C peptides (negative control sera). The amino acid 
residues of the two specific SV40 VP peptides show low 
homology with the BKV and JCV VP4-6. The synthetic 
peptides were synthesised using standard procedures and 
were purchased from UFPeptides s.r.l. (Ferrara, Italy)4,5. 
Indirect enzyme-linked immunosorbent assay
An indirect ELISA was developed and standardised 
to detect specific antibodies against SV40 in human 
sera using VP1 B and VP 2/3 C synthetic peptides4,5. 
Plates were coated with 5 μg of the selected peptide 
for each well and diluted in 100 μL of Coating 
Buffer (Candor Bioscience, Wangen, Germany). 
The peptide was then blocked with 200 μL/well of 
Blocking Solution (Candor Bioscience) at 37 °C for 90 
minutes before the primary antibody was added. The 
different wells were covered with 100 μL of solution 
containing the following sera: positive-control, 
represented by immune rabbit serum containing 
anti-SV40 antibodies, negative controls represented 
by anti-BKV and anti-JCV immune sera, and three 
human serum samples which were found to be SV40 
negative in our previous investigations4,5. The sera 
under analysis were diluted 1:20 in Low Cross-Buffer 
(Candor Bioscience). Each sample was analysed three 
times. The secondary antibody was added in a solution 
containing a goat anti-human IgG heavy and light chain 
specific peroxidase-conjugate (Calbiochem-Merck, 
Darmstadt, Germany) diluted 1:10,000 in Low Cross-
Buffer. The samples were then treated with 100 μL of 
2,2'-azino-bis 3-ethylbenzthiazoline-6-sulfonic acid 
(ABTS) solution (Sigma-Aldrich, Milan, Italy) and 
then read on the spectrophotometer (Thermo Electron 
Corporation, model Multiskan EX, Vantaa, Finland) 
at a wavelength (λ) of 405 nm. This approach detects 
the colour intensity by optical density (OD) in wells 
in which immunocomplexes are formed. The cut-off 
point was determined in each assay by an OD reading 
of three negative controls, which were added to the 
standard deviation and multiplied three times (+3SD). 
Sera with antibodies against SV40 were considered 
VP-positive if they reacted to both peptides of the late 
region and when sera that had been analysed three 
times by indirect ELISA gave the same positive result.
SV40 specificity of the indirect enzyme-linked 
immunosorbent assay employing synthetic peptides 
mimicking the VP antigens
In previous investigations, comparative computer-
assisted analyses using the BLAST programme were 
carried out with the SV40 VP peptides B and C and 
the corresponding amino acid sequences of the new 
human polyomaviruses and hundreds of different 
BKV and JCV serotypes4,5. Results indicate a low 
homology for the BKV and JCV prototypes and other 
polyomaviruses4,5.
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Indirect ELISA data indicate that the two SV40 
peptides B and C did not cross-react with the BKV 
and JCV hyperimmune sera (negative controls), 
as described before4,5. Briefly, hyperimmune sera 
against SV40 and BKV were obtained in rabbits 
that had been inoculated with purified viral stocks 
as previously reported4. The serum against JCV 
was kindly provided by Dr. Major (NIH, Bethesda, 
MD, USA)4,5. The anti-BKV immune serum was 
titered using a haemagglutination inhibition test 
employing human group O, Rh+ red blood cells4. 
Anti-SV40 serum was titered by a neutralisation 
assay4.
SV40 VP1 B and VP2/3 C mimotopes were 
selected as they react specifically in indirect ELISA 
with the rabbit hyperimmune serum that had been 
experimentally immunised with SV40 (positive 
control)4,5. The human peptide hNPS, amino acid 
sequence SFRNGVGTGMKKTSFQRAKS, was 
employed as a negative control peptide4,5.
Serum samples tested by indirect ELISA diluted at 
1/20 were considered SV40-positive when the OD was 
above 0.17-0.19, according to the spectrophotometric 
reading. Indeed, this cut-off point represents the value 
that discriminates SV40-negative samples (with OD 
below 0.17-0.19) from SV40-positive ones (with OD 
above 0.17-0.19). The positive control, represented by 
the SV40 hyperimmune serum, had an OD of up to 1.8, 
while the two JCV and BKV hyperimmune sera, which 
were employed as negative controls, had an OD of less 
than 0.1.
Statistical analysis 
Statistical analyses were performed using Prism 
software (GraphPad, San Diego, CA, USA). Data 
are presented as a percentage of positive samples. 
Differences among proportions were calculated by the 
chi-square test for independence in the contingency 
tables. 
Results 
In the first step of our investigation, an indirect 
ELISA was employed to test serum samples taken 
from patients affected by transfusion-dependent 
thalassaemia major (n=190; female=105, male=85) 
and control, healthy blood donors (n=251; female=33, 
males=218). The patients were aged 20 to 50 years, 
with a median age of 31 years. The median age of the 
controls was the same. 
Serum samples had been diluted at 1/20, for reactivity 
to SV40 epitopes from VP1, peptide B. The prevalence 
of serum samples from patients with thalassaemia which 
reacted with the SV40 VP1 B mimotope was 24% overall 
(45/190). The prevalence in subjects aged 20-30, 31-40, 
and 41-50 years was 19% (11/58), 22% (23/103), and 
38% (11/29), respectively (Table I).
The overall prevalence of serum samples from 
healthy blood donors, employed as controls, which 
reacted with the SV40 VP1 B mimotope was 17% 
(44/251). In this instance, the prevalence in subjects 
aged 20-30, 31-40, and 41-50 years was 10%, 19%, and 
20%, respectively (Table I). 
In the ELISA experiments, the human peptide hNPS14 
was employed as a negative control peptide. Data 
indicate that this negative control peptide did not react 
with 89 SV40-positive sera. The OD value was usually 
in the range of 0.088-0.098, which is consistent with the 
OD for SV40-negative sera.
The same assay was then used to detect IgG class 
serum antibodies against SV40 VP2/3 epitopes, which 
are known as VP2/3 C peptide. It turned out that serum 
samples reacted with the SV40 VP2/3 C peptide as had 
been detected previously for the VP1 B peptide in the 
respective cohorts of patients and controls. Conversely, 
seronegative samples for the SV40 VP1 B peptide failed 
to react with SV40 VP2/3 C epitopes. The exceptions 
were negligible and consisted of a few serum samples 
which were found to be negative for VP1 B, while 
testing positive for VP2/3 C peptide, and vice versa. 
The difference was not statistically significant (p>0.05) 
(Tables I and II). 
Table I - Prevalence of immunoglobulin G (IgG) 
antibodies reacting with simian virus 40 (SV40) 
viral peptide (VP) mimotopes.
Age (years) Number of samples  Number of positive samples (%)
VP B VP C VP (B+C)
20-30 58 15 (26) 12 (21) 11 (19)
31-40 103 25 (24) 28 (27) 23 (22)
41-50 29 12 (41) 11 (38) 11 (38)
20-50 Total 190 52 (27) 51 (27) 45 (24)
Human sera were from thalassemia patients. Statistical analysis was 
performed with the chi-square test. The different prevalence of SV40 
antibodies between the cohorts of thalassaemia patients was not statistically 
significant (p>0.05).
Table II - Prevalence of immunoglobulin G (IgG) 
antibodies reacting with SV40 viral peptide (VP) 
mimotopes.
Age (years) Number of samples  Number of positive samples (%)
VP B VP C VP (B+C)
20-30 50 8 (16) 6 (12) 5 (10)
31-40 90 22 (24) 20 (22) 17 (19)
41-50 111 25 (22) 22 (20) 22 (20)
20-50 Total 251 52 (21) 51 (20) 44 (17)
Human sera were from blood donors. Statistical analysis was performed with 
the chi-square test. The different prevalence of SV40 antibodies between the 
cohorts of blood donors was not statistically significant (p>0.05).
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In this study, only samples that tested positive for 
both the VP1 B and VP2/3 C peptides were considered 
SV40 positive. 
Combining these data, the overall prevalence for 
SV40 antibodies was 17% (Table I). SV40-positive 
sera tested by indirect ELISA diluted 1/20 had a general 
cut-off, by spectrophotometric reading, in the range 
of 0.17-0.19 OD. This cut-off represents the value 
that discriminates SV40-negative (sample below OD 
0.17-0.19) from SV40-positive samples (above OD 
0.17-0.19). The positive control, represented by the 
SV40 hyperimmune serum, had an OD of up to 1.8, 
while the two JCV and BKV hyperimmune sera, which 
were employed as negative controls, had an OD of less 
than 0.1. 
The two indirect ELISA, with two distinct VP 
peptides, gave overlapping results, thus confirming the 
presence of anti-SV40 VP antibodies in human sera from 
patients and controls (Tables I and II, Figure 1).
The seroprevalence of SV40 in human sera was 
analysed in detail, with regards to age, gender and 
geographic region of the patients and blood donors. 
Indirect ELISA data indicated that the prevalence of 
SV40 antibodies is similar in cohorts of individuals with 
the same age and gender, despite coming from different 
regions in Italy (data not shown). 
In this investigation, in each of the three age groups 
the patients affected by thalassaemia major had an 
higher prevalence of SV40 antibodies compared to the 
healthy blood donors of the same age. However only the 
difference in prevalence of SV40 antibodies in the oldest 
group was statistically significantly different (patients, 
38% versus healthy blood donors, 20%; p=0.04). The 
results are summarised in Tables I and II, Figure 1.
The serological profiles of serum antibody reactivity 
to SV40 mimotopes are presented in Figure 2. 
Discussion 
SV40 is an oncogenic virus that was inadvertently 
administered to human populations worldwide in the 
1960s by contaminated vaccines, mainly anti-polio 
vaccines, produced in naturally infected monkey kidney 
cells naturally infected with SV402,3,11,12. Accumulating 
data suggest that SV40, spreading by different routes, is 
able to infect humans as well as Asian macaques. SV40 
sequences have been found in blood specimens from 
normal individuals13,15 as well as in tumours of different 
histotypes, including non-Hodgkin's lymphomas9,10,16. 
However, it is worth mentioning that other groups failed 
to detect SV40 footprints in human specimens2.
Figure 1 - Prevalence of SV40-positive serum samples in patients 
with thalassaemia and in healthy blood donors.
Statistical analysis was performed with the chi-square test. 
Statistical analysis revealed significant differences in the 
prevalence of SV40 between thalassaemia patients aged 41-
50 years old and the cohort of healthy blood donors of the 
same age (p=0.04). No statistically significant differences in 
SV40 seroprevalence were found between the other cohorts of 
thalassaemic patients and their control groups of blood donors. 
Significance levels are indicated in the figure (*p<0.05).
Figure 2 - Serological profile of serum antibody reactivity to SV40 mimotopes VP B+C. 
 Immunological data are from healthy blood donors and from patients affected by thalassaemia. Results are presented 
as values of OD readings at λ 405 nm, of serum samples diluted at 1:20, detected in indirect ELISA. In scatter dot 
plotting, each plot represents the dispersion of OD values to a mean level indicated by the line inside the scatter with 
standard error of the mean (SEM) for each group of subjects analysed.
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In previous investigations we showed that linear 
peptides VP1 B and VP2/3 C resemble natural SV40 
linear epitopes, constituting a docking site for the serum 
antibody repertoire directed against both linear and 
conformational antigens4-7. On these grounds, serum 
samples from patients and blood donors were analysed 
for their reactivity to SV40 epitopes from viral capsid 
proteins using an indirect ELISA. The findings indicate 
that the overall prevalence of SV40 antibodies in 
patients affected by thalassaemia major and in healthy 
controls, aged from 20-50 year old, is 24% and 17%, 
respectively. It is important to note that the prevalence 
of SV40 in human sera detected by this immunological 
study does not differ substantially from that reported in 
previous studies carried out in the USA and UK using 
neutralisation testing against SV40 infectivity, which is 
considered the gold standard for measuring the presence 
of the SV40 antibody17-19. A similar prevalence of SV40 
sequences in normal individuals was found in earlier 
investigations by polymerase chain reaction assays 
(PCR) in peripheral blood mononuclear cell/buffy coat 
samples13,20-22. 
Taken together, the data from the ELISA indicate 
that natural SV40 infection occurs at a lower prevalence 
in both patients and normal individuals compared 
with the high prevalence of infection of the two well-
characterised human BK and JC polyomaviruses, which 
is in the range of 60-90%. The prevalence of anti-SV40 
serum antibodies increases with age, reaching 38% and 
20% in patients and controls, respectively, aged from 
41-50 year old. 
It has been shown that SV40 is present in the urine, 
stool, tonsil and blood specimens of children and 
adults suggesting that different ways of transmission 
are responsible for SV40 infection by the urinary, 
oro-faecal, respiratory and haematic routes23-26. These 
data seem to confirm the findings in earlier studies on 
subjects administered SV40-contaminated vaccinèes 
by different routes. Indeed, in these vaccines, SV40 
was detected/isolated after a number of days or weeks, 
either in stools or from throats due to the administration 
of contaminated vaccines as an oral or nasal spray27,28. 
However, these findings differ from those of other 
immunological studies in which SV40 antibodies were 
either absent or their prevalence was very low29,30. 
These previous findings were affected by some degree 
of cross-reactivity. Indeed, VLP or VP1 employed as 
antigens contain many epitopes in common with SV40, 
BK and JC polyomaviruses. In these investigations, 
the immune sera were pre-absorbed with BKV and 
JCV antigens in an attempt to give SV40 specificity 
to the assay. This procedure may eliminate/reduce the 
presence of SV40 antibodies in analysed sera31. Until 
now technical artefacts did not allow an estimation 
of the real prevalence of antibodies against SV40 in 
the population. SV40 synthetic peptides, employed as 
mimotopes/antigens in ELISA, were selected because 
they do not cross-react with BKV and JCV. This ELISA 
allowed us to estimate the prevalence of specific SV40 
antibodies against the structural protein antigens in 
serum samples from healthy blood donors4, children6, 
elderly subjects8, patients with mesothelioma5 and 
those with breast cancer7. This result, together with 
data obtained in other several studies, mainly carried 
out using PCR techniques, suggested that SV40 may be 
transmitted in humans by horizontal infections. 
It was found that the prevalence of antibodies against 
SV40 was higher in the cohort of transfusion-dependent 
thalassaemia patients than in the controls. The increase 
in prevalence of antibodies against viruses with age is a 
common feature. On the other hand, one may speculate 
that in the past SV40 could have been transmitted by 
transfusion with whole blood. Indeed, the difference 
in the prevalence between thalassaemic patients and 
controls was statistically significant only in the group 
aged 41-50 years. The significantly higher prevalence 
in the oldest cohort could be due to the fact that these 
patients received whole blood in their childhood and, 
subsequently, non-filtered red cells. Intracellular viruses 
including SV40, can be transmitted more easily with 
transfusions containing leucocytes. It is also possible that 
thalassaemia patients acquired SV40 antibody passively 
from blood transfusions. 
Recent investigations reported that older 
thalassaemic patients may develop specific tumours. 
Iron accumulation and hepatitis B and C viruses are 
considered among carcinogenic agents32-34. One may 
speculate that SV40, which is a small DNA tumour 
virus, could be an additional oncogenic risk factor for 
the oldest thalassaemia cohort.
Our study has several weaknesses. In fact it is a 
retrospective study and we do not have proof of absence 
of SV40 antibodies before the onset of transfusion or 
that SV40 was present in the blood that these patients 
received. 
The higher prevalence of serum antibodies in older 
thalassaemia patients compared to controls suggests 
that transfusion of whole blood may be associated with 
the acquisition of SV40 or antibodies against the virus, 
but a possible confounding of the association by other 
factors makes interpretation and conclusion difficult. In 
addition, due to the age distribution in the thalassemia 
population, the number of patients in the older cohort 
is small, and this may add a bias in the analysis of the 
results. However, the transfusion of packed red cells or 
filtered blood appears to be safe as there is no significant 
increase in SV40 seropositivity in thalassaemic 
subjects managed in this way compared with the rate 
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in controls. Other routes of SV40, or a closely related 
yet undiscovered human polyomavirus, transmission/
infection might be much more common than current 
transfusion practice.
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